North Carolina Patent of the Month – March 2024

Brii Biosciences, Inc., a biomedical company focused on tackling public health challenges, has been granted a patent for a new combination therapy for HIV infections. Their innovative approach combines a capsid inhibitor with an adenosine derivative, offering new hope in the fight against this devastating disease.

HIV, the virus responsible for AIDS, has posed significant challenges to researchers and healthcare professionals for decades. While treatments exist, the emergence of drug-resistant strains and issues with medication adherence have hindered efforts to control the spread of the virus and provide effective therapy.

Brii Biosciences’ method addresses these challenges head-on. By combining a capsid inhibitor with an adenosine derivative, they’ve developed a powerful treatment regimen that targets multiple aspects of the virus’s replication cycle. The capsid inhibitor works by disrupting the virus’s ability to integrate its genetic material into the host cell’s DNA, while the adenosine derivative inhibits the activity of reverse transcriptase, a key enzyme involved in viral replication.

What sets Brii Biosciences’ approach apart is not just its efficacy, but also its potential to improve patient outcomes through reduced dosing frequency. By offering a long-acting treatment option, patients may no longer need to adhere to a daily medication schedule, potentially improving adherence and quality of life for those living with HIV.

The versatility of their method means it could be beneficial for a wide range of patients, including those with highly treatment-experienced HIV, individuals with multidrug-resistant strains, and even those at risk of infection who are undertaking pre-exposure prophylaxis.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts